Why BGPT?
logo

Check Claims Before You Publish

See how your reported results read as versioned evidence records — linked to experiments and limitations.Know what the science actually supports before you trust the answer.

Press Enter ↵ to review claims


     Quick Explanation



    Anne Meehan (name-disambiguation critical): Based on the provided raw-data extracts, I can rigorously evaluate two retrovirology mechanistic studies (HIV-1 integrase/LEDGF interference; and lentiviral RNA–Gag trafficking), but the supplied excerpts appear to center on other named authors—so I cannot confidently attribute authorship/impact to “Anne Meehan” without a precise publication list or ORCID.



     Long Explanation



    BGPT Author Review — Anne Meehan

    Date context: 2026-03-29 • Evidence mode: raw-data extracts provided in the prompt

    1) Provenance & Identity Checks (skeptical, falsifiable)

    • Name ambiguity red-flag: “Anne Meehan” can refer to multiple distinct scholarly identities; the prompt includes multiple OpenAlex matches with different display names (e.g., “Anne M. Meehan”, “K. Meehan”, etc.). Without an ORCID or a verified author list for the specific DOIs below, I cannot safely attribute scientific credit to the intended Anne Meehan.
    • Attribution limitation: The two raw-data entries you provided are specific papers with particular author lists implied by the citations, but the excerpted datasets do not include an explicit mapping of those papers to “Anne Meehan”. Therefore, my scientific-strength assessment below is constrained to the mechanistic rigor visible in the provided studies, not their authorship attribution to Anne Meehan.

    2) What we can evaluate from your provided raw-data extracts

    Paper A (HIV-1 integrase accessibility & dominant interference via LEDGF/p75 interaction):
    • Study theme: LEDGF/p75-derived “dominant interference” proteins can prenuclearly expose HIV-1 integrase, block integration, and show synergy with LEDGF depletion; localization-targeted constructs suggest the antiviral mechanism is structure/location-dependent.
    • Evidence in extract includes multiple orthogonal assays: luciferase infectivity readouts, 2-LTR circle qPCR, integration detection via Alu-anchored PCR, Western/IF localization, and cell-type comparisons including primary human macrophages.
    Paper B (live-cell co-trafficking of lentiviral genomic RNAs and Gag):
    • Study theme: MS2-based live-cell imaging indicates that genomic RNAs require intact encapsidation signals and Gag to traffic to plasma membrane/endosomal compartments, with potential association near the nuclear envelope; comparison is made between HIV-1 and FIV.
    • Evidence in extract includes engineered reporters (24× MS2 stem-loops), live confocal imaging, co-localization metrics, dependency tests using RNA packaging-signal mutants, and Gag myristoylation (G2A) mutants.

    3) Visual evidence from the provided extracts (raw numeric points)

    Source values are limited to the numeric examples explicitly provided in the prompt extract for Paper A.
    Values are as stated in the Paper B prompt extract: colocalization 17.1% (n=356 cells) vs 0.0% (n=308) under intact vs packaging-signal deleted conditions.
    Extracted puncta counts: 381 puncta for “+RNA” vs 324 for “−RNA”, with cell counts also provided in the prompt extract.

    4) Scientific strength signals visible in the provided work (how to “score” rigor)

    Strengths (pro-rigor)

    • Orthogonal readouts and mechanistic hooks (Paper A): the extract indicates multiple independent assays for infection outcome and integration-related readouts (luciferase infectivity, 2-LTR circles, integration PCR, imaging/localization), which reduces the risk of single-assay artifacts.
    • Dependency engineering (Paper B): using intact vs packaging-signal-deleted RNAs provides a clear causal perturbation that tests whether RNA trafficking requires packaging competence and/or Gag association.
    • Localization-targeted perturbations (Paper A): NETC/PK targeting and inactive D366N mutant controls (as described in extract) help separate “where/what state of IN is accessible” from generic toxicity.

    Limitations & uncertainty (what could mislead)

    • Overexpression / tagging artifacts: both extracted limitations mention that DI constructs and MS2-tagged systems may perturb native stoichiometry or localization. That means mechanism claims can be “true in the engineered system” but uncertain in physiological infection contexts.
    • Mechanistic inference not direct measurement: Paper A’s DI “prenuclear exposure” interpretation can be consistent with assays (e.g., integration blocking and 2-LTR changes) yet still remain model-dependent without direct real-time IN–host factor accessibility measurements.
    • Attribution gap to “Anne Meehan”: even if the studies are strong, the provided prompt does not confirm that Anne Meehan is an author on these exact DOIs; therefore any author-performance scoring is underdetermined by the evidence supplied.

    5) What I would need to score “Anne Meehan” specifically (disproof test)

    • A verified ORCID (or an unambiguous author-page / publication list) linking “Anne Meehan” to the specific DOIs above.
    • Optionally: the set of 5–20 key publications for “Anne Meehan” with DOIs, so I can assess: study design quality, orthogonal evidence, reproducibility signals, and whether conclusions replicate across models.
    This will iteratively extract and compare experimental evidence from the cited DOIs and produce a tighter author-attribution check.


    Feedback:    

    Updated: March 30, 2026

     BGPT Author Review



    Scientific Quality

    40%

    The scientific content shown in the provided extracts looks methodologically substantial (multi-assay triangulation in Paper A; engineered dependency + live-cell imaging quantification in Paper B). However, the evidence does not clearly establish that “Anne Meehan” authored these studies, so attribution is uncertain; additionally, both studies rely on engineered/overexpression and tagging systems, making physiology generalization partially uncertain.



    Communication Quality

    60%

    Communication quality cannot be fully judged from extracts alone; the provided summaries emphasize experimental design and limitations, suggesting reasonable clarity, but I cannot evaluate writing style, narrative control, or target-audience calibration.



    Author Novelty

    60%

    The mechanistic questions (IN accessibility via host-factor interaction; Gag–RNA trafficking choreography via live-cell MS2 imaging) are conceptually distinct and appear novel in their experimental framing, though novelty magnitude cannot be quantified without the author’s full publication record and comparative citation context.



    Scientific Rigor

    70%

    Rigor signals are visible: orthogonal assays, explicit mutant/targeting controls, and quantitative imaging colocalization with stated cell counts. Still, inferential mechanism claims and engineered system limitations reduce certainty about physiological mechanisms; reproducibility cannot be judged from the extract alone.

     Analysis Wizard



    It will extract and compare the prompt’s reported numeric outputs from the two specified DOIs, then generate cross-paper plots of fold-inhibition and colocalization dependency to support a mechanism-quality audit.



     Hypothesis Graveyard



    A simplistic “DI blocks integration by preventing nuclear import” explanation is less preferred if PK-restricted DI still increases 2-LTR circles without impairing nuclear import, implying a post-entry integration block rather than solely trafficking failure.


    A “Gag independently drags any RNA to the plasma membrane” model is less supported if PM colocalization collapses to ~0% when the RNA encapsidation signal is deleted, indicating packaging competence is necessary for RNA recruitment.

     Science Art


    Author Review: Anne Meehan Science Art

     Science Movie



    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT